Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This therapeutic combination is a composite bone graft substitute that utilizes the 'diamond concept' of bone healing by integrating osteogenic, osteoconductive, and osteoinductive elements. It consists of **autologous bone marrow stem cells (BMSCs)**, which provide the cellular machinery (osteogenesis) for new bone formation; **tricalcium phosphate (TCP)**, a synthetic ceramic that serves as a porous, resorbable scaffold (osteoconduction) for cell attachment and mineral deposition; and **demineralized bone matrix (DBM)**, an allograft-derived matrix that provides essential growth factors, primarily bone morphogenetic proteins (BMPs), to trigger the differentiation of progenitor cells into bone-forming osteoblasts (osteoinduction). This combination is frequently employed in complex orthopedic procedures, including the treatment of non-unions, large bone defects, and spinal fusions, where a single-component graft may be insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow stem cells + tricalcium phosphate + demineralized bone matrix.